Possible lansoprazole-induced eosinophilic syndrome
Abstract
OBJECTIVE: To report a case of myalgia with eosinophilia related to lansoprazole administration.
CASE SUMMARY: A 50-year-old white woman developed severe myalgia 1 week after starting lansoprazole. During the treatment course, the patient was also found to have eosinophilia. The myalgia and eosinophilia resolved 40 days after lansoprazole was stopped and 18 days after prednisone therapy was begun. The patient was not rechallenged with lansoprazole.
DISCUSSION: To our knowledge, this is the first reported case of lansoprazole-induced eosinophilic syndrome. Clinically, it is difficult to distinguish between eosinophilia-myalgia syndrome and eosinophilic fasciitis, which are probably part of a continuum of eosinophilic disorders. This patient presented with symptoms of both syndromes. Although other causes cannot be completely ruled out, the time course strongly suggests that lansoprazole was the causative agent.
CONCLUSIONS: It is important to consider medications when diagnosing patients with hypereosinophilia and/or myalgia.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.